Articles

A new variation of femtosecond laser-assisted 'big bubble' deep anterior lamellar keratoplasty uses the laser to create an intrastromal channel serves as a pathway for the insertion of the air injection

Review of the year 2010

A review of the year in cataract & refractive, retina and glaucoma. Shows three industry experts view on their highs of the year and the changes they've experienced as well as what the future holds for 2011

Results from preclinical testing including a formal Good Laboratory Practice toxicity study, support the safety of a gene transfer agent, AAV2-sFLT01, when administered intravitreally. A phase I safety and tolerability study of this agent is currently underway.

Acquisition announced

Optos plc has announced its proposed acquisition of the entire issued shared capital of Opto Global Holdings for up to $14.75 million.

Title

Summary

A recent study has shown that the AcrySof toric IOL is more stable and provides better vision in cataract patients with pre-existing astigmatism, compared with an AcrySof spherical IOL.

Corneal arcus has been associated with higher intraocular pressure (IOP) and lower central corneal thickness (CCT), according to a recent study.

i-Optics has announced the successful closure of its third financing round with an investment of €4.2 million, which will enable the company to launch its first product for 2011 early

The FDA has cleared an age-adjusted retinal nerve fibre layer thickness normative database for a proprietary ocular coherence tomography (OCT) device, Spectralis (Heidelberg Engineering).

The ACI 7000 corneal inlay has shown safety and efficacy over a two-year study period in presbyopia patients, according to a study published in the Journal of Refractive Surgery.

Curcumin-based treatment Norflo, has been shown to alleviate the symptoms of anterior uveitis in a recent study published in Clinical Ophthalmology, indicating a potential role for the anti-inflammatory treatment curcumin in eye inflammatory and degenerative conditions.

Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME).